Drug Profile
YH IMD2
Alternative Names: YH-IMD2; YH_IMD2Latest Information Update: 10 Dec 2015
Price :
$50
*
At a glance
- Originator Yuhan
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hyperlipidaemia; Hypertension
Most Recent Events
- 10 Dec 2015 Discontinued - Preclinical for Hyperlipidaemia in South Korea (PO)
- 10 Dec 2015 Discontinued - Preclinical for Hypertension in South Korea (PO)
- 23 Aug 2012 Preclinical trials in Hyperlipidaemia in South Korea (PO)